公告子公司中天（上海）生物科技有限公司今日下午接獲中國國家藥品監督管理局藥品審評中心（CDE）書面通知書，正式受理ON101糖尿病足部傷口潰瘍新藥醫藥產品註冊申請（NDA）
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.